Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,483.00+0.48%ETH$2,450.63+1.72%GOLD$4,381.60-0.13%OIL$101.18-1.22%
Smart Investors Daily
TN

NASDAQ · TNGX

Tango Therapeutics, Inc.

Healthcare · Biotechnology

$23.35

Up+$0.14 (+0.60%)

Updated Sep 17, 2026, 9:02 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.01B
P/E ratio
-6.93
Dividend yield
0.00%
52-week range
$6.69 – $34.39
Volume
2.84M
Avg. volume
3.27M

Price performance

TNGX price history

1M range · 20 trading sessions · Daily adjusted prices

TNGX closed at $23.35 after 20 trading sessions, down 7.34% for the selected period.

Last close
$23.35
Period change
-7.34%
Period low
$22.32
Period high
$25.47
Daily close
View OHLC price history
TNGX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$24.17$24.39$23.00$23.352.84M
Sep 15, 2026$24.55$24.55$23.59$23.891.79M
Sep 14, 2026$23.98$24.99$23.44$24.542.01M
Sep 11, 2026$23.72$24.625$23.185$23.782.28M
Sep 10, 2026$23.16$24.30$23.16$23.373.44M
Sep 9, 2026$22.99$25.52$22.63$24.004.66M
Sep 8, 2026$22.50$23.08$22.26$22.702.42M
Sep 4, 2026$22.48$22.94$22.29$22.521.46M
Sep 3, 2026$22.50$22.785$22.13$22.761.34M
Sep 2, 2026$22.62$23.122$21.635$22.321.92M
Sep 1, 2026$22.60$23.06$22.07$22.351.54M
Aug 31, 2026$23.28$23.50$22.61$22.841.85M
Aug 28, 2026$24.93$25.085$23.275$23.342M
Aug 27, 2026$25.39$26.85$25.24$25.282.04M
Aug 26, 2026$24.65$27.00$24.26$25.473.17M
Aug 25, 2026$25.04$25.61$24.35$24.772.28M
Aug 24, 2026$23.60$24.68$22.91$24.512.09M
Aug 21, 2026$23.95$24.36$23.48$23.882.49M
Aug 20, 2026$25.51$25.67$23.145$23.512.06M
Aug 19, 2026$26.19$26.34$25.01$25.201.82M

Latest TNGX news

The latest Smart Investors Daily articles mentioning TNGX.

Stock researchCompany · Overview

TNGX research

Overview

Company profile and research snapshot.

Company profile

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.50
Implied upside
—
Analysts
15
TNGX recent ratings
DateFirmRatingTarget
Aug 18, 2026HC Wainwright & Co.Buy—
Aug 12, 2026GuggenheimBuy—
Jul 17, 2026MizuhoOutperform—
Jul 15, 2026JP MorganOverweight—
Jun 29, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey

Tango Therapeutics stock reaction and recent performance Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company’s recent performance. Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about...

Yahoo · Sep 3, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for th

Yahoo · Sep 1, 2026

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be a

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By